Adalimumab

Adalimumab, a leading anti-TNFα therapy, is essential in treating autoimmune diseases like rheumatoid arthritis (RA), especially after the failure of first-line treatments such as methotrexate. Despite its efficacy in reducing disease activity, its use can lead to the development of anti-drug antibodies (ADAs), which diminish its therapeutic effect by reducing drug bioavailability. Traditional methods for monitoring ADAs, including ELISA and antigen-binding tests, face limitations due to interference from factors like rheumatoid factors and therapeutic drug levels. This study introduced a novel cytometric assay capable of simultaneously detecting adalimumab concentrations and ADAs, overcoming key interferences. The findings revealed significant links between disease severity markers, ADA levels, and a protective role of anti-hinge antibodies. These insights improve therapeutic monitoring and patient outcomes.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.